Structure–activity relationship of natural and synthetic coumarin derivatives against Mycobacterium tuberculosis

Author:

Pires Claudia TA1ORCID,Scodro Regiane BL2ORCID,Cortez Diógenes AG34,Brenzan Mislaine A3ORCID,Siqueira Vera LD1ORCID,Caleffi-Ferracioli Katiany R1ORCID,Vieira Lucas CC5ORCID,Monteiro Júlia L6ORCID,Corrêa Arlene G6ORCID,Cardoso Rosilene F12ORCID

Affiliation:

1. Programa de Pós-Graduação em Biociências e Fisiopatologia, Universidade Estadual de Maringá, 87020-900 Maringá, Paraná, 87020-900, Brazil

2. Programa de Pós-Graduação em Ciências da Saúde, Universidade Estadual de Maringá, Maringá, Paraná, 87020-900, Brazil

3. Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, Maringá, Paraná, 87020-900, Brazil

4. Programa de Pós-Graduação em Promoção da Saúde, Unicesumar – Centro Universitário, Maringá, Paraná, 87050-390, Brazil

5. Instituto de Engenharia, Universidade Federal de Mato Grosso, Cuiabá, Mato Grosso, 78060-900, Brazil

6. Laboratório de Síntese de Produtos Naturais – LSPN, Departamento de Química, Universidade Federal de São Carlos, São Carlos, São Paulo, 13565-905, Brazil

Abstract

Aim: Eight coumarin derivatives (1a–h) obtained from natural (-)-mammea A/BB (1) and 13 synthetic coumarins (2–14) had their cytotoxicity and biological activity evaluated against Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates. Materials & methods: Anti- M. tuberculosis activity was evaluated by resazurin microtiter assay plate, and the cytotoxicity of natural and synthetic products using J774A.1 macrophages by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Results: Compounds 1g, 5, 6, 12 and 14 were more active against M. tuberculosis H37Rv and multidrug-resistant clinical isolates with MIC values ranging from 15.6 to 62.5 μg/ml. Conclusion: These results demonstrate that the coumarin derivatives were active against multidrug-resistant clinical isolates, becoming potential candidates to be used in the treatment of resistant tuberculosis.

Publisher

Future Science Ltd

Subject

Drug Discovery,Pharmacology,Molecular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3